Cargando…
Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study
BACKGROUND: In trials evaluating perioperative chemotherapy for gastric cancer, which serve as the basis for treatment guidelines, patients are selected. The generalizability of these trial findings to older patients is uncertain. METHODS: This population-based retrospective cohort study compared th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361849/ https://www.ncbi.nlm.nih.gov/pubmed/37285071 http://dx.doi.org/10.1007/s10120-023-01404-2 |
_version_ | 1785076298755866624 |
---|---|
author | Keywani, Kammy Borgstein, Alexander B. J. Eshuis, Wietse J. Pape, Marieke Versteeg, Kathelijn S. Derks, Sarah van Laarhoven, Hanneke W. M. Gisbertz, Suzanne S. Verhoeven, Rob H. A. van Berge Henegouwen, Mark I. |
author_facet | Keywani, Kammy Borgstein, Alexander B. J. Eshuis, Wietse J. Pape, Marieke Versteeg, Kathelijn S. Derks, Sarah van Laarhoven, Hanneke W. M. Gisbertz, Suzanne S. Verhoeven, Rob H. A. van Berge Henegouwen, Mark I. |
author_sort | Keywani, Kammy |
collection | PubMed |
description | BACKGROUND: In trials evaluating perioperative chemotherapy for gastric cancer, which serve as the basis for treatment guidelines, patients are selected. The generalizability of these trial findings to older patients is uncertain. METHODS: This population-based retrospective cohort study compared the survival outcomes of patients ≥ 75 years with gastric adenocarcinoma treated with or without neoadjuvant chemotherapy between 2015 and 2019. Additionally, the percentage of patients < 75 years and ≥ 75 years who did not proceeded to surgery after receiving neoadjuvant chemotherapy were examined. RESULTS: A total of 1995 patients, of whom 1249 aged < 75 years and 746 aged ≥ 75 years, were included. In the group of patients ≥ 75 years, 275 patients received neoadjuvant chemotherapy and 471 patients were directly scheduled for gastrectomy. Patients ≥ 75 years treated with or without neoadjuvant chemotherapy differed significantly from one and another in characteristics. Overall survival of patients ≥ 75 years treated with or without neoadjuvant chemotherapy was not significantly different (median 34.9 vs. 32.3 months; P = 0.506), also after adjusting for potential confounders (HR 0.87; P = 0.263). Of patients ≥ 75 years who received neoadjuvant chemotherapy, 43 (15.6%) did not proceed to surgery compared to 111 (8.9%) patients < 75 years (P < 0.001). CONCLUSION: Patients ≥ 75 years treated with or without chemotherapy were highly selected, and overall survival was not significantly different between both groups. Nonetheless, the proportion of patients who did not proceed to surgery following neoadjuvant chemotherapy was higher in patients ≥ 75 years compared to patients < 75 years. Therefore, neoadjuvant chemotherapy should be considered with more caution in patients ≥ 75 years, while identifying those who may benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10120-023-01404-2. |
format | Online Article Text |
id | pubmed-10361849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-103618492023-07-23 Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study Keywani, Kammy Borgstein, Alexander B. J. Eshuis, Wietse J. Pape, Marieke Versteeg, Kathelijn S. Derks, Sarah van Laarhoven, Hanneke W. M. Gisbertz, Suzanne S. Verhoeven, Rob H. A. van Berge Henegouwen, Mark I. Gastric Cancer Original Article BACKGROUND: In trials evaluating perioperative chemotherapy for gastric cancer, which serve as the basis for treatment guidelines, patients are selected. The generalizability of these trial findings to older patients is uncertain. METHODS: This population-based retrospective cohort study compared the survival outcomes of patients ≥ 75 years with gastric adenocarcinoma treated with or without neoadjuvant chemotherapy between 2015 and 2019. Additionally, the percentage of patients < 75 years and ≥ 75 years who did not proceeded to surgery after receiving neoadjuvant chemotherapy were examined. RESULTS: A total of 1995 patients, of whom 1249 aged < 75 years and 746 aged ≥ 75 years, were included. In the group of patients ≥ 75 years, 275 patients received neoadjuvant chemotherapy and 471 patients were directly scheduled for gastrectomy. Patients ≥ 75 years treated with or without neoadjuvant chemotherapy differed significantly from one and another in characteristics. Overall survival of patients ≥ 75 years treated with or without neoadjuvant chemotherapy was not significantly different (median 34.9 vs. 32.3 months; P = 0.506), also after adjusting for potential confounders (HR 0.87; P = 0.263). Of patients ≥ 75 years who received neoadjuvant chemotherapy, 43 (15.6%) did not proceed to surgery compared to 111 (8.9%) patients < 75 years (P < 0.001). CONCLUSION: Patients ≥ 75 years treated with or without chemotherapy were highly selected, and overall survival was not significantly different between both groups. Nonetheless, the proportion of patients who did not proceed to surgery following neoadjuvant chemotherapy was higher in patients ≥ 75 years compared to patients < 75 years. Therefore, neoadjuvant chemotherapy should be considered with more caution in patients ≥ 75 years, while identifying those who may benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10120-023-01404-2. Springer Nature Singapore 2023-06-07 2023 /pmc/articles/PMC10361849/ /pubmed/37285071 http://dx.doi.org/10.1007/s10120-023-01404-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Keywani, Kammy Borgstein, Alexander B. J. Eshuis, Wietse J. Pape, Marieke Versteeg, Kathelijn S. Derks, Sarah van Laarhoven, Hanneke W. M. Gisbertz, Suzanne S. Verhoeven, Rob H. A. van Berge Henegouwen, Mark I. Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study |
title | Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study |
title_full | Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study |
title_fullStr | Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study |
title_full_unstemmed | Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study |
title_short | Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study |
title_sort | neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361849/ https://www.ncbi.nlm.nih.gov/pubmed/37285071 http://dx.doi.org/10.1007/s10120-023-01404-2 |
work_keys_str_mv | AT keywanikammy neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT borgsteinalexanderbj neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT eshuiswietsej neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT papemarieke neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT versteegkathelijns neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT derkssarah neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT vanlaarhovenhannekewm neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT gisbertzsuzannes neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT verhoevenrobha neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy AT vanbergehenegouwenmarki neoadjuvantchemotherapyinolderpatientswithgastriccancerundergoingsurgeryapopulationbasedcohortstudy |